Amgen (AMGN)
(Delayed Data from NSDQ)
$319.66 USD
+2.18 (0.69%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $319.25 -0.41 (-0.13%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$319.66 USD
+2.18 (0.69%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $319.25 -0.41 (-0.13%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Zacks News
Amgen (AMGN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $270.12, moving -1.85% from the previous trading session.
Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $264.39 in the latest trading session, marking a +1.05% move from the prior day.
Dow Jones Beats S&P 500 in 2022: 5 Hot Stocks
by Sweta Killa
The Dow Jones fared as the best of the indexes and five stocks -- Chevron (CVX), Merck (MRK), Travelers (TRV), Amgen (AMGN), and Caterpillar (CAT) -- gained in double-digits in 2022.
Amgen (AMGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $263.16 in the latest trading session, marking a +0.67% move from the prior day.
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zacks Investment Ideas feature highlights: Caterpillar, Chevron and Amgen
by Zacks Equity Research
Caterpillar, Chevron and Amgen have been highlighted in this Investment Ideas article.
3 Top Performing Blue-Chips of 2022
by Derek Lewis
Many investors have flocked to blue-chip stocks in 2022 to shield themselves from volatility. Can the strength of these three stocks spill into 2023?
Amgen (AMGN) Stock Moves -0.2%: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $263.39, moving -0.2% from the previous trading session.
Mirati's (MRTX) Krazati Gets Breakthrough Therapy Tag for CRC
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy designation to Mirati's (MRTX) Krazati (adagrasib) for treating patients with advanced, KRAS-mutated colorectal cancer.
The Zacks Analyst Blog Highlights Broadcom, United Parcel Service, Amgen, America Movil and Manulife Financial
by Zacks Equity Research
Broadcom, United Parcel Service, Amgen, America Movil and Manulife Financial are part of the Zacks top Analyst Blog.
Q4 Earnings Season Update and Analyst Reports for Broadcom, UPS & Amgen
by Sheraz Mian
Today's Research Daily features update on the Q4 earnings season and new research reports on Broadcom (AVGO), UPS (UPS), Amgen (AMGN) and 16 other stocks.
Amgen (AMGN) Stock Moves -0.64%: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $265.70, marking a -0.64% move from the previous day.
Cytokinetics (CYTK) Up Despite Unfavorable FDA Committee Voting
by Zacks Equity Research
Cytokinetics (CYTK) gets an unfavorable recommendation from CRDAC on omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction.
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
5 Stocks to Watch on Dividend Hikes Before 2022 Wraps Up
by Zacks Equity Research
Investors may keep a tab on LW, NUE, PWRr, TTC, and AMGN which have lately hiked their dividend payments to reward investors.
Biotech Stock Roundup: HZNP Surges on AMGN Offer, TRDA Gains on VRTX Deal & More
by Zacks Equity Research
Acquisitions news from HZNP and AMGN form the key highlights from the biotech sector during the past week.
Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $272.26, marking a -1.63% move from the previous day.
Trending Today: 5 Stocks in the News
by Andrew Rocco
So far this week, several stocks have had headline-driven catalysts. We will cover 5 stocks trending in the news.
Amgen to Buy Horizon Therapeutics: ETFs to Bet On
by Sweta Killa
Amgen (AMGN) has agreed to buy Horizon Therapeutics PLC (HZNP) for $27.8 billion. This put the spotlight on pharma ETFs, which could be the best way for investors to tap the opportunity arising from the proposed deal.
5 Dow Stocks That Helped the Index Minimize Loss in 2022
by Vaishali Doshi
Here we have shortlisted five stocks - CVX, MRK, AMGN, TRV and IBM- that have fared better than the Dow Jones Index this year and have more upside potential for investment consideration.
Company News for Dec 13, 2022
by Zacks Equity Research
Companies in The News Are: COUP,HZNP,AMGN,RIVN,BA
Mirati (MRTX) Up on FDA Nod to Adagrasib for KRAS Mutated NSCLC
by Zacks Equity Research
The accelerated approval of Mirati Therapeutics' (MRTX) Krazati is based on ORR and DOR data from the phase II registration-enabling cohort of the KRYSTAL-1 study.
Amgen (AMGN) to Buy Horizon Therapeutics For $27.8 Billion
by Zacks Equity Research
Amgen (AMGN) wins the race to buy Horizon Therapeutics and makes an acquisition offer of $27.8 billion.
Wall Street Awaits Key Fed FOMC Decision
by Zacks Equity Research
Wall Street Awaits Key Fed FOMC Decision